About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, June 23rd, 2017

The QualityStocks
Daily Stock List


Nanophase Technologies Corp. (NANX)

Wall Street Resources, SmarTrend Newsletters, Investment Contrarians, RedChip, Profit Confidential, Schaeffer’s, CoolPennyStocks, BullRally, Stock Rich, HotOTC, Penny Invest, StockEgg, and Stealth Stocks reported earlier on Nanophase Technologies Corp. (NANX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nanophase Technologies Corp. is a technology leader in nanomaterials and advanced nanoengineered products. The Company provides nanoengineered solutions for numerous industrial product applications. It assists its customers in succeeding, with proprietary and patent protected technologies. These technologies permit them to create inventive products. Nanophase Technologies is based in Romeoville, Illinois and the Company lists on the OTC Markets Group’s OTCQB.

Nanophase Technologies creates products with original performance attributes from two ISO 9001:2008 and ISO 14001 facilities. The Company’s products include Aluminum Oxide, Antimony Tin Oxide, Bismuth Oxide, Cerium Oxide, Iron Oxide, and Zinc Oxide. Nano metal oxides provide UV protection across plastics, exterior coatings, and textile applications. Infrared absorbing particles create high clarity, energy saving films and interlayers.

The Company’s nano and submicron Aluminum Oxide imparts scratch resistance to coatings for wood, laminates, packaging, graphic arts, as well as electronics. Nano metal oxide technology improves the longevity and capacity of zinc anode-based batteries.

Nanophase Technologies delivers commercial quantity and quality nanoparticles, coated nanoparticles, and nanoparticle dispersions in an array of media. It produces engineered nanomaterial products for use in a variety of markets. These markets include Surface Finishing, Exterior Coatings, Personal Care, Plastics, Scratch Resistant Coatings, and Textiles.  
Pertaining to nanoparticle production technology, the traditional and most usual manufacturing methods employed at the Company are plasma-based. The Physical Vapor Synthesis (PVS) and NanoArc® Synthesis (NAS) methods use transferred and non-transferred electric arcs to vaporize precursor materials.

These are subsequently carefully condensed to produce nanoparticles with desired properties. These methods have been used to produce simple and complex, multi-component mixed metal oxides.

Recently, Nanophase Technologies reported financial results for Q1 ended March 31, 2017. Revenue for Q1 was $3.5 million, in comparison to the $2.2 million reported during Q1 of 2016. The Net Income for the quarter was $47,000, or $0.00 per share, versus a Net Loss of $0.6 million, or $0.02 per share, for the comparable 2016 quarter.

Nanophase Technologies has no debt. It finished the quarter with roughly $1.5 million in cash and cash equivalents. 

Nanophase Technologies Corp. (NANX), closed Friday's trading session at $0.65, down 4.41%, on 8,300 volume with 5 trades. The average volume for the last 60 days is 6,655 and the stock's 52-week low/high is $0.40/$0.8701.

AntriaBio, Inc. (ANTB)

BUYINS.NET, Ceocast News, and PennyStocks24 reported earlier on AntriaBio, Inc. (ANTB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AntriaBio, Inc. is a biopharmaceutical company concentrating on developing novel extended release therapies. It develops novel extended release therapies through combining proprietary formulation and manufacturing capabilities with well-known molecules to considerably improve standards of care. The Company develops inventive approaches to fulfill unmet clinical needs through applying its formulation capabilities to improve existing therapies.  In essence, AntriaBio specializes in the development of unique drug therapies for patients with diabetes and metabolic diseases. OTCQB-listed, AntriaBio is headquartered in Louisville, Colorado.

The Company’s lead product candidate is AB101. This is an injectable once-weekly basal insulin for type 1 and type 2 diabetes. AB101 addresses a $10 billion market where the current standard of care is a once-daily basal insulin injection.

AB101 is formulated from human recombinant insulin. This is different from existing basal insulin replacement therapies, which use synthetic insulin analogues.

AB101 is presently in preclinical development. It is to be administered by subcutaneous injection. The design of the formulation is to release human insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin.

AntriaBio successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101. The studies assessed the receptor pharmacology, pharmacokinetics, and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients.

AntriaBio has another product candidate in its product development pipeline – AB301. As a potential treatment for patients with type 2 diabetes, AB301 is a weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, the Company’s basal insulin lead product candidate.

Last month, AntriaBio announced that it formally engaged Prosciento to conduct AntriaBio's first-in-human clinical study of AB101, the once-weekly basal insulin for patients with diabetes mellitus. Prosciento, previously known as Profil Institute for Clinical Research, is a clinical research organization (CRO) specializing in diabetes mellitus and other metabolic diseases.

Earlier this month, AntriaBio announced that it filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB101. Its intention is to subsequently initiate a Phase 1 first-in-human clinical study. The first-in-human Phase 1 study will measure the safety and tolerability, pharmacokinetics and time-action profile of single ascending doses of AB101, administered to subjects with type 1 diabetes mellitus.

AntriaBio, Inc. (ANTB), closed Friday's trading session at $1.20, even for the day, on 16 volume with 1 trade. The average volume for the last 60 days is 8,199 and the stock's 52-week low/high is $0.625/$2.00.

RespireRx Pharmaceuticals, Inc. (RSPI)

InvestorsHub, MarketWatch, Marketwired, and Barchart reported on RespireRx Pharmaceuticals, Inc. (RSPI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders. These disorders include sleep apneas and drug-induced respiratory depression. The Company formerly went by the name Cortex Pharmaceuticals, Inc. It changed its name to RespireRx Pharmaceuticals, Inc. in December of 2015. Established in 1987, RespireRx Pharmaceuticals shares trade on the OTC Markets Group’s OTCQB. The Company is based in Glen Rock, New Jersey.

RespireRx Pharmaceuticals has filed more than 400 patents in the United States and offshore, which claim composition of matter, use, formulation, dosage, and mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system indications.

RespireRx’s pharmaceutical candidates in development are derived from two platforms. One platform of medicines undergoing development by the Company is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain.  Several ampakines, in oral and injectable form, are undergoing development by RespireRx Pharmaceuticals for the treatment of a variety of breathing disorders.

The other platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol. Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA). Under a license agreement with the University of Illinois, RespireRx Pharmaceuticals has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders.  

In December 2016, the Company announced positive results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University. The PACE trial is a Phase 2B study of dronabinol for the treatment of obstructive sleep apnea (OSA).

RespireRx states that the PACE trial clearly demonstrates that dronabinol significantly improves the primary outcome measures of Apnea Hypopnea Index (AHI), daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS) and overall patient satisfaction as measured by the Treatment Satisfaction Questionnaire for Medications (TSQM).

RespireRx Pharmaceuticals’ Senior Vice President of Research and Development, Mr. Richard Purcell presented a poster session entitled: "OPIOIDS AND SLEEP APNEA: ANTAGONISM OF REMIFENTANIL INDUCED RESPIRATORY DEPRESSION BY CX1739 IN TWO CLINICAL MODELS OF OPIOID INDUCED RESPIRATORY DEPRESSION" at the Sleep 2017 conference in Boston, Massachusetts on June 6, 2017. 

Mr. Purcell said, "The focus of the Phase IIA clinical trial was to advance the clinical proof of concept that CX1739, one of the Company's low-impact Ampakines®, has clinical utility for the treatment of respiratory depression resulting from high doses of opioids for pain management. This research demonstrates not only the safety of the Ampakines, but also target-engagement of CNS neurons that drive respiratory function. The data provide a clear clinical development path for CX1739 for treating CNS-driven respiratory disorders like central sleep apnea and spinal cord injury."

RespireRx Pharmaceuticals, Inc. (RSPI), closed Friday's trading session at $2.25, up 9.76%, on 1,131 volume with 2 trades. The average volume for the last 60 days is 756 and the stock's 52-week low/high is $1.50/$12.025.

BioHiTech Global, Inc. (BHTG)

Zacks, MarketWatch, and TradingView reported on BioHiTech Global, Inc. (BHTG), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

BioHiTech Global, Inc. is a green technology company with its corporate headquarters in Chestnut Ridge, New York. It provides unique data-driven solutions for food waste disposal. The Company develops and deploys innovative and disruptive waste management technologies. It is a leader in zero waste solutions for businesses and municipalities of all sizes.

BioHiTech Global provides waste management solutions to a global customer base covering a complete suite of technology-based disposal options that can have a significant impact on waste generation. This is while providing a true zero landfill environment. The Company collaborated with Natural Systems Utilities to convert commercial food waste to energy. The Company also launched BioHiTech Cirrus. This is a mobile application (app) for consummate insight into the waste stream.

BioHiTech Global expanded its waste stream product offering last year with the launch of Entsorga North America. The Entsorga North America undertaking will expand BioHiTech’s product offering towards providing disruptive, clean technology solutions that progress the global movement towards sustainability and zero waste initiatives.

Entsorga North America will manage Apple Valley Waste Conversions LLC, which is an Entsorga North America part-owned subsidiary, the company that holds an exclusive license to deploy the proprietary Entstorga HEBioT Mechanical Biological Treatment (MBT) technology throughout the northeastern U.S. The HEBioT MBT system converts food waste, plastics, and other carbon-based materials from the mixed municipal solid waste (MSW) stream into an Environmental Protection Agency (EPA) recognized alternative fuel source.

BioHiTech Global has initiated a strategic rollout plan for the deployment of its proprietary MBT Technology for Waste Disposal and Recycling. Its intention (the first phase of its rollout strategy) is to locate two HEBioT facilities in the Northeast U.S. It entered into Letters of Intent (LOIs) to purchase property and solid waste permits for the two planned locations. This proprietary HEBioT process recovers nearly 80 percent of municipal solid waste. Additionally, BioHiTech Global intends to purchase an equity interest in the first ever HEBioT facility in the U.S., now under construction in Martinsburg, West Virginia.

BioHiTech Global has launched its BioHiTech Alto™. This is a next generation interactive industrial communication technology. It enables users to communicate intelligently with industrial equipment in real-time.  BioHiTech Alto is a vital new component of the Company’s complete food waste solution that uses data and analytics to help drive smarter business decisions.

Recently, BioHiTech Global announced the signing of a contract with the Town of New Windsor, New York. This contract is for the acquisition of a 12-acre site planned for the Company's second Resource Recovery Facility employing the proprietary HEBioT technology for the disposal and recycling of mixed municipal solid waste (MSW).

Moreover, last month, BioHiTech Global announced its continued expansion across the United States by shipping the 100th digester to the Company’s largest customer to date, the Federal Bureau of Prisons.  Last week, BioHiTech Global announced the installation of its Revolution Series Sprout digester in the Food Lab at the Seaport District N.Y.C. (previously known as the South Street Seaport). The rebranded Seaport District N.Y.C. is part of a $730 million-dollar renovation of 400,000 square feet of retail space. This includes the iconic Pier 17.

BioHiTech Global, Inc. (BHTG), closed Friday's trading session at $2.85, down 1.72%, on 7,621 volume with 30 trades. The average volume for the last 60 days is 8,068 and the stock's 52-week low/high is $1.50/$3.90.

ProGreen US, Inc. (PGUS)

Penny Stock Prodigy and Promotion Stock Secrets reported earlier on ProGreen US, Inc. (PGUS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ProGreen US, Inc. engages mainly with investments in agricultural and real estate projects in Baja California, Mexico. It is centering on intensifying its property investments in Baja California, Mexico, by way of its joint venture (JV) partnership with Inmobiliaria Contel, and also through its subsidiary Procon Baja JV. Concerning ProGreen US’ Baja Project, it entered into a JV with a Mexican landowner, Inmobiliaria Contel and have jointly created Pro Baja, the Company’s newest JV with ProGreen owning 51 percent and Inmobiliaria Contel 49 percent.

ProGreen US has its headquarters in Bloomfield, Michigan. However, it is moving its headquarters this month to San Diego, California. Moreover, it has established an office location in Ensenada, which will serve as headquarters for all of its activities in Baja California. Procon and Contel will operate from this location. ProGreen has completed funding for its first agriculture operations in Baja California.

Contel is presently active in the high margin produce industry, growing crops for exporters to the U.S. market, with an abundance of land available for expansion under its JV partnership. Procon has recently acquired 5,100 acres of land with 4.7 miles of oceanfront on the Bay of El Rosario, for which a master plan is being drawn for the development of a very large, totally green, global vacation and retirement community named "Cielo Mar."

ProGreen US has completed development of the first tract of land that comprises about 300 acres. Of this, some 100 usable acres have been cleared. The Company was able to drill three wells providing a wealth of water.

In addition, ProGreen US earlier signed another agreement for a further 1,900 acres (500-800 usable for farming), and a 3-year option for 11,500 acres (1000-2500 usable for farming). This land, once developed and prepared, will be offered for long term lease (10-15 years), with the JV holding the title.

ProGreen US announced in December 2016 that Inmobiliaria Contel, with which ProGreen has the JV partnership, declared that, in the process of establishing the required agricultural infrastructure for the JV, they established a direct channel with two different U.S. fresh produce importers. This enables Inmobiliaria Contel to manage produce growing operations on their own, or in partnership with other growers on the 300 acres of land that forms part of the JV Agreement with ProGreen US, entered into in February 2016. Inmobiliaria Contel, as a producer, will be able to grow more than one cycle annually on the property.

At the end of May 2017, ProGreen US announced that the First Reservation Offer for its ocean front development in Baja California, Cielo Mar, is ending. The Company states that 24 of the 30 lots that were offered now have executed reservation agreements. This leaves only 6 available with one additional reservation request pending. In addition, there are 6 commitments for early construction, once the planning has been approved.

ProGreen US, Inc. (PGUS), closed Friday's trading session at $0.02028, up 1.40%, on 469,833 volume with 16 trades. The average volume for the last 60 days is 621,173 and the stock's 52-week low/high is $0.0042/$0.03.


The QualityStocks
Company Corner


Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0232, off by 3.33%, on 4,796,389 volume with 298 trades. The stock’s average daily volume over the past 60 days is 5,405,276, and its 52-week low/high is $0.0062/$0.142.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of NNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication is entitled "Diverse Opportunities Aplenty for Investors Interested in the Marijuana Market." The editorial highlights the assorted investment options in the burgeoning marijuana sector. To view the full publication, visit: https://www.networknewswire.com/diverse-opportunities-aplenty-investors-interested-marijuana-market/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Discussing the Growing Variety of Investment Prospects in the Marijuana Market

SinglePoint Completes $1 Million Funding to Continue its BitCoin Cannabis Payment Solutions Development

NetworkNewsWire Announces Publication Discussing the Use of Digital Currency in the Marijuana Market

Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.12, up 17.65%, on 4,604,924 volume with 353 trades. The stock’s average daily volume over the past 60 days is 2,931,166, and its 52-week low/high is $0.0023/$0.1315.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.


WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Player's Network, Inc. Appoints Geoffrey Lawrence, Nevada Assistant State Controller, as Chief Financial Officer, Chief Compliance Officer

Player's Network, Inc. CEO Featured on MoneyTV with Donald Baillargeon, 6/2

Player's Network, Inc. Subsidiary Awarded Two Nevada Recreational Marijuana Licenses

National Waste Management Holdings, Inc. (NWMH)

The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.095573, up 13.64%, on 21,096 volume with 4 trades. The stock’s average daily volume over the past 60 days is 18,745, and its 52-week low/high is $0.06/$0.145.

National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.

National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.

In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.

Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer

National Waste Management Holdings, Inc. Company Blog

National Waste Management Holdings, Inc. News:

National Waste Management Holdings Inc. Reports Full-Year 2016 Results, Triple-Digit Revenue Growth

National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC

National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling

Stealth Technologies Inc. (STTH)

The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.0149, up 35.45%, on 24,100 volume with 2 trades. The stock’s average daily volume over the past 60 days is 36,253, and its 52-week low/high is $0.01/$0.05.

Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.

The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.

StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.

The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.

Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.

Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer

Stealth Technologies Inc. Company Blog

Stealth Technologies Inc. News:

Stealth Technologies Announces 5 New Products

Stealth Technologies Highlights Opportunities from Attendance at Leading Real Estate, Home Staging Conference

NetworkNewsWire Releases Exclusive Audio Interview with Stealth Technologies, Inc. (STTH)

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.26, off by 6.61%, on 405,070 volume with 174 trades. The stock’s average daily volume over the past 60 days is 989,716, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media

InMed Announces Agreement to Advance a Topical Formulation of INM-750

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(OPXAW) +168.69%


OnPoint Stock Alert
(MECK) +96.88%


Trader Power News
(AVEO) +41.67%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251